Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)

Part of paid clinical trials in Chula Vista, California.

Sponsor
AstraZeneca
Study ID
NCT01165268
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

Study Details

It is anticipated that 7 days of oral administration of 10 mg dapagliflozin will reduce the renal glucose reabsorption similarly in healthy subjects and in subjects with T2DM.

Key Dates

Start date
Aug 31, 2010
Status verified
Nov 2016
Primary completion
Dec 31, 2010
Completion
Dec 31, 2010

Study Design

Enrollment
24 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Active Comparator: Dapagliflozin (T2DM)
  • Active Comparator: Dapagliflozin (Healthy Subjects)

Primary Outcome Measure

The reduction in TmG after 7 days of oral administration of 10 mg of dapagliflozin [ Time Frame: Before 7 days of oral administration of 10 mg of dapagliflozin ]

Locations (1)

FacilityCityStateZIPSite coordinators
Profil Institute For Clinical Research, Inc.Chula VistaCalifornia91911-

Find similar trials in Chula Vista, CA

By condition
Type 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Profil Institute For Clinical Research, Inc.· Chula Vista, CA

Related Studies